Chapter 2: Drug Receptors and Pharmacodynamics - In-depth Notes

Learning Objectives

  • Define key terms: receptors, affinity, EC50, Kd, Bmax, spare receptors, competitive antagonists, irreversible antagonists, chemical antagonists, physiological antagonists.

  • Compare and contrast: agonists, antagonists (competitive, irreversible), partial agonists, inverse agonists, allosteric agents regarding dose/response curves.

  • Discuss the “spare receptor” theory.

  • Signal transduction pathways for receptor groups: steroid receptors, tyrosine kinase receptors, cytokine receptors (Jak/Stat), ligand-gated channels, G protein-coupled receptors.

  • Desensitization of G protein-coupled receptors: list the steps involved.

  • Receptor desensitization vs. downregulation: understanding the differences.

  • Second messenger pathways: mechanisms for cAMP and phosphoinositides.

  • Define terminology: potency, efficacy, LD50, ED50, TD50, therapeutic index, and responses after drug administration (idiosyncratic, hyporeactive, hyperreactive, tolerance, tachyphylaxis).

  • Distinguish between the beneficial and toxic effects of drugs.

Receptor Concepts

  • Receptors: Components that interact with drugs, initiating biological effects.

  • Affinity: The strength of drug-receptor binding; influences the concentration of drug needed for effect.

  • Receptor Selectivity: Determined by drug characteristics (size, shape, charge), affecting binding.

  • Functional Categories:

    • Agonist: Activates receptor function upon binding.

    • Antagonist: Binds without activating receptor function.

Types of Receptors

  • Neurotransmitters: Chemical messengers in the nervous system.

  • Autacoids: Act locally for brief durations.

  • Hormones: Systemic signaling with prolonged effects.

  • Enzymes: Drugs may inhibit or activate enzyme action.

  • Transport Proteins: e.g., digoxin inhibits Na/K+ ATPase.

  • Structural Proteins: Affect cell structure and function, e.g., colchicine in inflammation.

Drug Concentration and Response

  • Response to Drug Concentration: Dose increases response until maximum effect (Emax) is reached.

  • Key Definitions:

    • EC50: Concentration for half-maximal response.

    • Kd: Equilibrium dissociation constant for receptor-drug binding.

    • Bmax: Total concentration of receptors available.

The Spare Receptors Concept

  • Definition: Maximum response can occur with <100% receptor occupancy.

  • Examples:

    • Spare receptors can exist where only a fraction of receptors are bound to achieve full biological response.

Antagonists

  • Competitive Antagonists:

    • Bind reversibly, can inhibit agonist response depending on concentration.

  • Irreversible Antagonists:

    • Bind permanently or covalently, decreasing receptor availability irrespective of agonist concentration.

Partial Agonists

  • Produce lower responses at full receptor occupancy compared to full agonists; activation capability is reduced.

Other Types of Drug Antagonism

  • Chemical Antagonists: Bind and inactivate another drug.

  • Physiological Antagonists: Control functions through opposing regulatory pathways.

Signaling Mechanisms and Drug Action

  • Lipid-Soluble Agents: Cross cell membranes and bind to intracellular receptors, initiating transcription (e.g., steroid hormones).

  • Receptor Tyrosine Kinases: Ligand binding activates receptor dimerization leading to phosphorylation and diverse cellular responses.

  • Cytokine Receptors: Dimerize and activate JAK-STAT pathways impacting gene regulation.

  • Ligand-Gated Channels: Allow ion flux across membranes upon ligand binding.

  • G-Protein Coupled Receptors: Utilize a variety of G proteins to amplify signals through second messengers.

Receptor Regulation

  • Desensitization: Receptor response diminishes with prolonged exposure to ligand.

  • Downregulation: Reduction in receptor numbers over time, impacting sensitivity.

Second Messenger Pathways

  • cAMP Pathway:

    • Produced by adenylyl cyclase; leads to activation of protein kinase A (PKA) influencing multiple pathways and gene expression.

  • Calcium and Phosphoinositide Pathway: Activation of phospholipase C, resulting in IP3 and DAG, which initiate calcium release and PKC activation.

Variations in Drug Response

  • Idiosyncratic: Unusual drug responses possibly due to genetic or immunologic differences.

  • Tolerance: Diminished response from chronic drug use.

  • Tachyphylaxis: Rapid decrease in response to a drug after initial exposures.

Clinical Implications

  • Understanding potency and efficacy is critical for effective therapy and drug development.

  • Therapeutic indices guide clinical decision-making to ensure safety and efficacy.

  1. Define key terms:

    • Receptors: Components that interact with drugs, initiating biological effects.

    • Affinity: The strength of drug-receptor binding; influences the concentration of drug needed for effect.

    • EC50: Concentration for half-maximal response.

    • Kd: Equilibrium dissociation constant for receptor-drug binding.

    • Bmax: Total concentration of receptors available.

    • Spare receptors: Maximum response can occur with <100% receptor occupancy; spare receptors can achieve full biological response with only a fraction of receptors bound.

    • Competitive antagonists: Bind reversibly, can inhibit agonist response depending on concentration.

    • Irreversible antagonists: Bind permanently or covalently, decreasing receptor availability irrespective of agonist concentration.

    • Chemical antagonists: Bind and inactivate another drug.

    • Physiological antagonists: Control functions through opposing regulatory pathways.

  2. Compare and contrast:

    • Agonists: Activate receptor function upon binding.

    • Antagonists: Bind without activating receptor function.

    • Partial agonists: Produce lower responses at full receptor occupancy compared to full agonists; activation capability is reduced.

    • Inverse agonists: Not mentioned in existing notes; these inhibit the action of agonists and stabilize receptors in their inactive state.

    • Allosteric agents: Also not mentioned, these bind to sites other than the active site to modulate receptor activity.

  3. Discuss the “spare receptor” theory:

    • Spare receptors can exist where only a fraction of receptors are bound to achieve a full biological response.

  4. Signal transduction pathways for receptor groups:

    • Steroid receptors: Lipid-soluble agents cross cell membranes and bind to intracellular receptors initiating transcription (e.g., steroid hormones).

    • Tyrosine kinase receptors: Ligand binding activates receptor dimerization leading to phosphorylation and diverse cellular responses.

    • Cytokine receptors: Dimerize and activate JAK-STAT pathways impacting gene regulation.

    • Ligand-gated channels: Allow ion flux across membranes upon ligand binding.

    • G protein-coupled receptors: Utilize a variety of G proteins to amplify signals through second messengers.

  5. Desensitization of G protein-coupled receptors:

    • Receptor response diminishes with prolonged exposure to ligand. Steps involved may include ligand binding, receptor phosphorylation, and receptor internalization.

  6. Receptor desensitization vs. downregulation:

    • Desensitization: Temporary loss of responsiveness upon continual ligand exposure.

    • Downregulation: Reduction in receptor numbers over time, leading to decreased sensitivity.

  7. Second messenger pathways:

    • cAMP Pathway: Produced by adenylyl cyclase; leads to activation of protein kinase A (PKA) influencing multiple pathways and gene expression.

    • Calcium and Phosphoinositide Pathway: Activation of phospholipase C, resulting in IP3 and DAG, which initiate calcium release and PKC activation.

  8. Define terminology:

    • Potency: The amount of drug needed to produce an effect.

    • Efficacy: The maximum effect that can be achieved with a drug.

    • LD50: Lethal dose for 50% of the population.

    • ED50: Effective dose for 50% of the population.

    • TD50: Toxic dose for 50% of the population.

    • Therapeutic index: Ratio of TD50 to ED50, indicating safety.

    • Responses after drug administration:

      • Idiosyncratic: Unusual drug responses possibly due to genetic or immunologic differences.

      • Hyporeactive: Reduced response to a drug.

      • Hyperreactive: Enhanced response to a drug.

      • Tolerance: Diminished response from chronic drug use.

      • Tachyphylaxis: Rapid decrease in response to a drug after initial exposures.

  9. Distinguish between the beneficial and toxic effects of drugs:

    • Understanding potency and efficacy is critical for effective therapy and drug development; therapeutic indices guide clinical decision-making to ensure safety and efficacy.